We use cookies for a better user experience. Read our Privacy Policy

I Agree

Antihypertensive Drugs Market

Antihypertensive Drugs Market (Therapy Type: Diuretics, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Blockers, Beta-blockers, Vasodilators, Calcium Channel Blockers, Renin Inhibitors, Alpha-blockers, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Antihypertensive Drugs Market Outlook 2031

  • The global market was valued at US$ 30.2 Bn in 2021
  • The global market is projected to grow at a CAGR of 3.0% from 2022 to 2031
  • The market is anticipated to reach more than US$ 40 Bn by the end of 2031

Analysts’ Viewpoint

Increase in launch of new drugs and diagnostic agents; and key industry developments such as collaborations and establishment of new R&D centers are likely to propel the global market. In 2017, Abbott Laboratories opened a new China R&D center to meet the evolving healthcare needs of local consumers in Shanghai.

Daiichi Sankyo collaborated with the University of California San Francisco’s Institute for Neurodegenerative Diseases for joint research and development of drugs and diagnostic agents for various neurodegenerative diseases.

Rise in disposable income and launch of new disease-modifying therapies are projected to propel the global market during the forecast period. Significant growth in telemedicine and e-Health apps is also likely to create long-term revenue opportunities for companies in the antihypertensive drugs market.

antihypertensive drugs market

Overview

Antihypertensive medications are used to treat high blood pressure. Different types of antihypertensive drugs are available in the market. These help lower blood pressure.

Some remove excess fluid and salt from the body, while others help relax and widen blood vessels or slow the heart rate. A person could respond better and experience fewer side effects to one drug than to another. Some patients require more than one antihypertensive agent to lower blood pressure.

Hypertension is a preventable risk factor for atherosclerotic disease and ischemic heart disease. A number of patients maintain suboptimal blood pressure control despite the availability of modern and effective antihypertensive drugs. Most hypertensive patients require a combination of antihypertensive agents to achieve treatment goals.

Under combination therapy, another class of blood pressure medication is added to the first drug to increase its effectiveness. The market has reasonably high unmet demand, which indicates the lack of effective products.

This presents significant opportunities for new entrants to capitalize on the unmet needs, largely due to poor patient compliance with products currently available in the market.

Trends in antihypertensive medication in stroke survivors could provide important insights into gaps in secondary prevention that can guide improved interventions in the future. Healthcare companies are increasing R&D in the field of genomics and resistant hypertension treatment to gain a competitive edge over other market players.

Request a sample to get extensive insights

Launch of New Disease-modifying Therapies to Drive Global Antihypertensive Drugs Market

Innovative antihypertensive drugs and drug therapies are expected to offer favorable outcomes, as these effectively target disease progression.

The current scenario in the global antihypertensive drugs Market is expected to change due to the launch of new therapies for diseases such as angiotensin II receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, and calcium channel blockers (CCB) during the forecast period.

Currently, physicians prescribe fewer diuretics and beta-blockers, common first-line agents for hypertension, and more ACE and CHF inhibitors. ACE inhibitors reduce mortality and morbidity in cardiovascular patients; however, this is not true for CCBs.

If control is not available on beta-blockers, diuretics, or ACE inhibitors, short-acting CHFs should be avoided and alternatives should be considered. Unlike ACE inhibitors, ARBs do not cause cough. Therefore, launch of innovative drug/therapeutic molecules with disease-modifying properties and improved efficacy and safety is expected to drive the global market in the next few years.

Promising Products in Pipeline to Boost Demand for Antihypertensive Drugs

Treatments for hypertension are relatively potent. Several drugs are being studied in clinical trials, including those with disease-modifying properties, better safety, and effectiveness, which can reduce disease progression significantly.

Launch of new products with improved efficiency and safety is expected to drive the market. Bayer's candesartan cilexetil/nifedipine (phase III), Boryung Pharmaceuticals' fimasartan/amlodipine (phase III), and Takeda Pharmaceuticals' diuretic azilsartan/amlodipine/hydrochlorothiazide (phase III) are some of the drugs under development.

Request a custom report on Antihypertensive Drugs Market

Companies Establish Stable Revenue Streams by Augmenting Production of Angiotensin Receptor Blockers

In terms of therapy type, the global market has been classified into diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, vasodilators, calcium channel blockers, renin inhibitors, alpha-blockers, others.

The angiotensin receptor blockers segment is projected to dominate the global antihypertensive drugs market during the forecast period. The segment is expected to grow at a high CAGR from 2021 to 2031. Angiotensin II receptor blockers (ARBs) have a similar effect to ACE inhibitors, another type of blood pressure drug, but work on a different mechanism.

High Salt Intake to Propel Demand for Antihypertensive Drugs for Primary Hypertension Management

Based on type, the global market has been bifurcated into primary hypertension and secondary hypertension. The primary hypertension segment is projected to dominate the global market during the forecast period. The segment is anticipated to grow at a high CAGR from 2021 to 2031.

Hypertension has become a global health concern over the last decade. In the developed world, salt intake is generally above the recommended quantity among children. Similar trend exists in the developing world. Positive sodium balance is needed for growth in the first year of life; however, high salt intake could have harmful cardiovascular consequences.

Increase in Geriatric Population with Comorbidities Driving Need for Combination Therapy

In terms of medication, the global antihypertensive drugs market has been segregated into monotherapy, combination therapy, and fixed dose combinations. The combination therapy segment is projected to dominate the market, with significant revenue share by 2031. The segment is anticipated to advance at a high CAGR from 2021 to 2031.

Rise in geriatric population with comorbid conditions such as congenital heart disease; and focus on combination therapies are driving the combination therapy segment. Thus, manufacturers are increasing the production of combination antihypertensive drugs to meet the needs of elderly patients with comorbidities.

Broad Medicine Portfolio to Boost Hospital Pharmacies Segment

Based on distribution channel, the global antihypertensive drugs market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment dominated the global market in 2021.

Hospital pharmacies usually stock a wide range of medicines, including specialized and investigational medications. Hospital pharmacies are increasing the availability of hypertension management devices to broaden their income sources.

Regional Outlook

North America dominated the global antihypertensive drugs market in 2021. The market in the region is projected to grow at a high CAGR from 2022 to 2031. North America is anticipated to sustain its market share during the forecast period.

High adoption of antihypertensive drugs in the U.S., increase in the number of approvals for new drugs by the U.S. FDA, and rise in percentage of people suffering from cardiovascular diseases in the U.S. and Canada contribute to North America's significant market share.

The market in Asia Pacific region is expected to grow at a high CAGR during the forecast period, owing to the large patient pool, increase in incidence of heart diseases, aging population, and high demand and export of drugs to Europe and North America.

Analysis of Key Players

The global antihypertensive drugs market is consolidated, with a small number of leading players accounting for major share. Large numbers of companies are investing in research & development activities. Diversification of product portfolios and mergers & acquisitions are important strategies adopted by key players.

Pfizer, Inc., Sanofi S.A, Novartis AG, Boehringer Ingelheim GmbH, Actelion Ltd., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited are the prominent players operating in the global market.

Key Developments in Global Antihypertensive Drugs Market

  • In April 2021, Radnor Biopharma developed a hormone-targeting treatment for hypertension
  • In 2018, CFDA provided a new clinical approval process for a company to proceed with a clinical trial if the Center for Drug Evaluation Act has no comments on the application within a given period of time
  • In July 2018, Daiichi Sankyo Company Limited's antihypertensive drug Sieweika (olmesartan amlodipine tablet) was officially approved in China

Each of these players has been profiled in the market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 30.2 Bn

Market Forecast Value in 2031

More than US$ 40 Bn

Growth Rate

(CAGR)

3.0%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Therapy Type
    • Diuretics
    • Angiotensin Converting Enzyme Inhibitors
    • Angiotensin Receptor Blockers
    • Beta-blockers
    • Vasodilators
    • Calcium Channel Blockers
    • Renin Inhibitors
    • Alpha-blockers
    • Others
  • Type
    • Primary Hypertension
    • Secondary Hypertension
  • Medication Type
    • Monotherapy
    • Combination Therapy
    • Fixed Dose Combinations
  • Distribution Channel
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Pfizer, Inc.
  • Sanofi S.A
  • Novartis AG
  • Boehringer Ingelheim GmbH
  • Actelion Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Daiichi Sankyo Company, Limited
  • Takeda Pharmaceutical Company Limited

Customization Scope

Available upon request

Pricing

Available upon request

Antihypertensive Drugs Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global antihypertensive drugs market in 2021?

The global market was valued at US$ 30.2 Bn in 2021

How big will be the global market in 2031?

The global market is projected to reach more than US$ 40 Bn by 2031

What was the CAGR of the global market from 2017 to 2021?

The global market grew at a CAGR of 3.0% from 2017 to 2021

What will be the CAGR of market during the forecast period (2022–2031)?

The global market is anticipated grow at a CAGR of 3.0% from 2022 to 2031

Which are the prominent trends that affect market growth?

Increase in geriatric population, promising products in pipeline, and launch of new disease-modifying therapies drive the global market

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global market during the forecast period

Who are the prominent players in the global market?

Prominent players in the global antihypertensive drugs market include Pfizer, Inc., Sanofi S.A, Novartis AG, Boehringer Ingelheim GmbH, Actelion Ltd., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Antihypertensive Drugs Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Antihypertensive Drugs Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Bn)

5. Market Outlook

    5.1. Key Industry Developments

    5.2. Impact scenario

    5.3. New product developments

6. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type

    6.1. Introduction & Definition

    6.2. Global Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017–2031

        6.2.1. Diuretics

            6.2.1.1. Thiazide diuretics

            6.2.1.2. Loop diuretics

            6.2.1.3. Potassium-sparing diuretics

        6.2.2. Angiotensin Converting Enzyme Inhibitors

        6.2.3. Angiotensin Receptor Blockers

        6.2.4. Beta-blockers

            6.2.4.1. Beta-1 Selective

            6.2.4.2. Intrinsic Sympathomimetic

        6.2.5. Vasodilators

        6.2.6. Calcium Channel Blockers

        6.2.7. Renin Inhibitors

        6.2.8. Alpha-blockers

        6.2.9. Others

    6.3. Global Antihypertensive Drugs Market Attractiveness, by Therapy Type

7. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type

    7.1. Introduction & Definition

    7.2. Global Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031

        7.2.1. Primary Hypertension

        7.2.2. Secondary Hypertension

    7.3. Global Antihypertensive Drugs Market Attractiveness, by Type

8. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type

    8.1. Introduction

    8.2. Global Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017–2031

        8.2.1. Monotherapy

        8.2.2. Combination Therapy

        8.2.3. Fixed Dose Combinations

    8.3. Global Antihypertensive Drugs Market Attractiveness, by Medication Type

9. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel

    9.1. Introduction

    9.2. Global Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031

        9.2.1. Retail Pharmacies

        9.2.2. Hospital Pharmacies

        9.2.3. Online Pharmacies

        9.2.4. Others

    9.3. Global Antihypertensive Drugs Market Attractiveness, by Distribution Channel

10. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Region

    10.1. Introduction

    10.2. Antihypertensive Drugs Market Value Forecast, by Region, 2017-2031

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Global Antihypertensive Drugs Market Attractiveness, by Region

11. North America Antihypertensive Drugs Market Analysis and Forecast

    11.1. Introduction

    11.2. North America Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031

        11.2.1. Diuretics

            11.2.1.1. Thiazide diuretics

            11.2.1.2. Loop diuretics

            11.2.1.3. Potassium-sparing diuretics

        11.2.2. Angiotensin Converting Enzyme Inhibitors

        11.2.3. Angiotensin Receptor Blockers

        11.2.4. Beta-blockers

            11.2.4.1. Beta-1 Selective

            11.2.4.2. Intrinsic Sympathomimetic

        11.2.5. Vasodilators

        11.2.6. Calcium Channel Blockers

        11.2.7. Renin Inhibitors

        11.2.8. Alpha-blockers

        11.2.9. Others

    11.3. North America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031

        11.3.1. Primary Hypertension

        11.3.2. Secondary Hypertension

    11.4. North America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031

        11.4.1. Monotherapy

        11.4.2. Combination Therapy

        11.4.3. Fixed Dose Combinations

        11.4.4. Others

    11.5. North America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031

        11.5.1. Retail Pharmacies

        11.5.2. Hospital Pharmacies

        11.5.3. Online Pharmacies

        11.5.4. Others

    11.6. North America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Antihypertensive Drugs Market Attractiveness Analysis

        11.7.1. By Therapy Type

        11.7.2. By Type

        11.7.3. By Medication Type

        11.7.4. By Distribution Channel

        11.7.5. By Country/Sub-region

12. Europe Antihypertensive Drugs Market Analysis and Forecast

    12.1. Introduction

    12.2. Europe Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031

        12.2.1. Diuretics

            12.2.1.1. Thiazide diuretics

            12.2.1.2. Loop diuretics

            12.2.1.3. Potassium-sparing diuretics

        12.2.2. Angiotensin Converting Enzyme Inhibitors

        12.2.3. Angiotensin Receptor Blockers

        12.2.4. Beta-blockers

            12.2.4.1. Beta-1 Selective

            12.2.4.2. Intrinsic Sympathomimetic

        12.2.5. Vasodilators

        12.2.6. Calcium Channel Blockers

        12.2.7. Renin Inhibitors

        12.2.8. Alpha-blockers

        12.2.9. Others

    12.3. Europe Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031

        12.3.1. Primary Hypertension

        12.3.2. Secondary Hypertension

    12.4. Europe Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031

        12.4.1. Monotherapy

        12.4.2. Combination Therapy

        12.4.3. Fixed Dose Combinations

        12.4.4. Others

    12.5. Europe Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031

        12.5.1. Retail Pharmacies

        12.5.2. Hospital Pharmacies

        12.5.3. Online Pharmacies

        12.5.4. Others

    12.6. Europe Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Europe Antihypertensive Drugs Market Attractiveness Analysis

        12.7.1. By Therapy Type

        12.7.2. By Type

        12.7.3. By Medication Type

        12.7.4. By Distribution Channel

        12.7.5. By Country/Sub-region

13. Asia Pacific Antihypertensive Drugs Market Analysis and Forecast

    13.1. Introduction

    13.2. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031

        13.2.1. Diuretics

            13.2.1.1. Thiazide diuretics

            13.2.1.2. Loop diuretics

            13.2.1.3. Potassium-sparing diuretics

        13.2.2. Angiotensin Converting Enzyme Inhibitors

        13.2.3. Angiotensin Receptor Blockers

        13.2.4. Beta-blockers

            13.2.4.1. Beta-1 Selective

            13.2.4.2. Intrinsic Sympathomimetic

        13.2.5. Vasodilators

        13.2.6. Calcium Channel Blockers

        13.2.7. Renin Inhibitors

        13.2.8. Alpha-blockers

        13.2.9. Others

    13.3. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031

        13.3.1. Primary Hypertension

        13.3.2. Secondary Hypertension

    13.4. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031

        13.4.1. Monotherapy

        13.4.2. Combination Therapy

        13.4.3. Fixed Dose Combinations

        13.4.4. Others

    13.5. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031

        13.5.1. Retail Pharmacies

        13.5.2. Hospital Pharmacies

        13.5.3. Online Pharmacies

        13.5.4. Others

    13.6. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031

        13.6.1. Japan

        13.6.2. China

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis

        13.7.1. By Therapy Type

        13.7.2. By Type

        13.7.3. By Medication Type

        13.7.4. By Distribution Channel

        13.7.5. By Country/Sub-region

14. Latin America Antihypertensive Drugs Market Analysis and Forecast

    14.1. Introduction

    14.2. Latin America Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031

        14.2.1. Diuretics

            14.2.1.1. Thiazide diuretics

            14.2.1.2. Loop diuretics

            14.2.1.3. Potassium-sparing diuretics

        14.2.2. Angiotensin Converting Enzyme Inhibitors

        14.2.3. Angiotensin Receptor Blockers

        14.2.4. Beta-blockers

            14.2.4.1. Beta-1 Selective

            14.2.4.2. Intrinsic Sympathomimetic

        14.2.5. Vasodilators

        14.2.6. Calcium Channel Blockers

        14.2.7. Renin Inhibitors

        14.2.8. Alpha-blockers

        14.2.9. Others

    14.3. Latin America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031

        14.3.1. Primary Hypertension

        14.3.2. Secondary Hypertension

    14.4. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031

        14.4.1. Monotherapy

        14.4.2. Combination Therapy

            14.4.2.1. Thiazide diuretics

            14.4.2.2. Loop diuretics

            14.4.2.3. Potassium-sparing diuretics

        14.4.3. Angiotensin Converting Enzyme Inhibitors

        14.4.4. Angiotensin Receptor Blockers

        14.4.5. Beta-blockers

            14.4.5.1. Beta-1 Selective

            14.4.5.2. Intrinsic Sympathomimetic

        14.4.6. Vasodilators

        14.4.7. Calcium Channel Blockers

        14.4.8. Renin Inhibitors

        14.4.9. Alpha-blockers

        14.4.10. Others

    14.5. Latin America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031

        14.5.1. Primary Hypertension

        14.5.2. Secondary Hypertension

    14.6. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031

        14.6.1. Monotherapy

        14.6.2. Combination Therapy

        14.6.3. Fixed Dose Combinations

        14.6.4. Others

    14.7. Latin America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031

        14.7.1. Retail Pharmacies

        14.7.2. Hospital Pharmacies

        14.7.3. Online Pharmacies

        14.7.4. Others

    14.8. Latin America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031

        14.8.1. Brazil

        14.8.2. Mexico

        14.8.3. Rest of Latin America

    14.9. Latin America Antihypertensive Drugs Market Attractiveness Analysis

        14.9.1. By Therapy Type

        14.9.2. By Type

        14.9.3. By Medication Type

        14.9.4. By Distribution Channel

        14.9.5. By Country/Sub-region

15. Middle East & Africa Antihypertensive Drugs Market Analysis and Forecast

    15.1. Introduction

    15.2. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031

        15.2.1. Diuretics

            15.2.1.1. Thiazide diuretics

            15.2.1.2. Loop diuretics

            15.2.1.3. Potassium-sparing diuretics

        15.2.2. Angiotensin Converting Enzyme Inhibitors

        15.2.3. Angiotensin Receptor Blockers

        15.2.4. Beta-blockers

            15.2.4.1. Beta-1 Selective

            15.2.4.2. Intrinsic Sympathomimetic

        15.2.5. Vasodilators

        15.2.6. Calcium Channel Blockers

        15.2.7. Renin Inhibitors

        15.2.8. Alpha-blockers

        15.2.9. Others

    15.3. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031

        15.3.1. Primary Hypertension

        15.3.2. Secondary Hypertension

    15.4. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031

        15.4.1. Monotherapy

        15.4.2. Combination Therapy

        15.4.3. Fixed Dose Combinations

        15.4.4. Others

    15.5. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031

        15.5.1. Retail Pharmacies

        15.5.2. Hospital Pharmacies

        15.5.3. Online Pharmacies

        15.5.4. Others

    15.6. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Israel

        15.6.4. Rest of Middle East & Africa

    15.7. Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis

        15.7.1. By Therapy Type

        15.7.2. By Type

        15.7.3. By Medication Type

        15.7.4. By Distribution Channel

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player - Competition Matrix (by tier and size of companies)

    16.2. Company Profiles

        16.2.1. Pfizer, Inc.

            16.2.1.1. Company Description

            16.2.1.2. Business Overview

            16.2.1.3. Financial Overview

            16.2.1.4. Strategic Overview

            16.2.1.5. SWOT Analysis

        16.2.2. Sanofi S.A

            16.2.2.1. Company Description

            16.2.2.2. Business Overview

            16.2.2.3. Financial Overview

            16.2.2.4. Strategic Overview

            16.2.2.5. SWOT Analysis

        16.2.3. Novartis AG

            16.2.3.1. Company Description

            16.2.3.2. Business Overview

            16.2.3.3. Financial Overview

            16.2.3.4. Strategic Overview

            16.2.3.5. SWOT Analysis

        16.2.4. Boehringer Ingelheim GmbH

            16.2.4.1. Company Description

            16.2.4.2. Business Overview

            16.2.4.3. Financial Overview

            16.2.4.4. Strategic Overview

            16.2.4.5. SWOT Analysis

        16.2.5. Actelion Ltd. (Johnson & Johnson Services, Inc.)

            16.2.5.1. Company Description

            16.2.5.2. Business Overview

            16.2.5.3. Financial Overview

            16.2.5.4. Strategic Overview

            16.2.5.5. SWOT Analysis

        16.2.6. F. Hoffmann-La Roche Ltd.

            16.2.6.1. Company Description

            16.2.6.2. Business Overview

            16.2.6.3. Financial Overview

            16.2.6.4. Strategic Overview

            16.2.6.5. SWOT Analysis

        16.2.7. Bayer AG

            16.2.7.1. Company Description

            16.2.7.2. Business Overview

            16.2.7.3. Financial Overview

            16.2.7.4. Strategic Overview

            16.2.7.5. SWOT Analysis

        16.2.8. Daiichi Sankyo Company, Limited

            16.2.8.1. Company Description

            16.2.8.2. Business Overview

            16.2.8.3. Financial Overview

            16.2.8.4. Strategic Overview

            16.2.8.5. SWOT Analysis

        16.2.9. Takeda Pharmaceutical Company Limited

            16.2.9.1. Company Description

            16.2.9.2. Business Overview

            16.2.9.3. Financial Overview

            16.2.9.4. Strategic Overview

            16.2.9.5. SWOT Analysis

List of Tables

Table 01: Global Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Therapy Type, 2017-2031

Table 02: Global Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Diuretics, 2017-2031

Table 03: Global Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Beta-blockers, 2017-2031

Table 04: Global Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Type, 2017-2031

Table 05: Global Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Medication Type, 2017-2031

Table 06: Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

Table 07: Global Antihypertensive Drugs Value (US$ Bn) Forecast, by Region, 2017-2031

Table 08: North America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Country, 2017-2031

Table 09: North America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type, 2017-2031

Table 10: North America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Diuretics, 2017-2031

Table 11: North America Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Beta-blockers, 2017-2031

Table 12: North America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type, 2017-2031

Table 13: North America Antihypertensive Drugs Market Size (US$ Bn) Forecast, by Medication Type, 2017-2031

Table 14: North America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

Table 15: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 16: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type, 2017-2031

Table 17: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Diuretics, 2017-2031

Table 18: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Beta-blockers, 2017-2031

Table 19: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type, 2017-2031

Table 20: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type, 2017-2031

Table 21: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

Table 22: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 23: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type, 2017-2031

Table 24: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Diuretics, 2017-2031

Table 25: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Beta-blockers, 2017-2031

Table 26: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type, 2017-2031

Table 27: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type, 2017-2031

Table 28: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

Table 29: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 30: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type, 2017-2031

Table 31: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Diuretics, 2017-2031

Table 32: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Beta-blockers, 2017-2031

Table 33: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type, 2017-2031

Table 34: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type, 2017-2031

Table 35: Latin America Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

Table 36: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 37: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type, 2017-2031

Table 38: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Diuretics, 2017-2031

Table 39: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Beta-blockers, 2017-2031

Table 40: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type, 2017-2031

Table 41: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type, 2017-2031

Table 42: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2017-2031

List of Figures

Figure 01: Global Antihypertensive Drugs Market Size Value (US$ Bn) Forecast, 2017-2031

Figure 02: Global Antihypertensive Drugs Market Value Share (%), by Therapy Type, 2017-2031

Figure 03: Global Antihypertensive Drugs Market Value Share (%), by Type, 2017-2031

Figure 04: Global Antihypertensive Drugs Market Value Share (%), by Distribution Channel, 2017-2031

Figure 05: Global Antihypertensive Drugs Market Value Share (%), by Distribution Channel, 2017-2031

Figure 06: Global Antihypertensive Drugs Market Value Share Analysis, by Therapy Type, 2017-2031

Figure 07: Global Antihypertensive Drugs Market Attractiveness Analysis, by Therapy Type, 2017-2031

Figure 08: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Diuretics, 2017-2031

Figure 09: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Angiotensin Converting Enzyme Inhibitors, 2017-2031

Figure 10: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Angiotensin Receptor Blockers, 2017-2031

Figure 11: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Beta-blockers, 2017-2031

Figure 12: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Vasodilators, 2017-2031

Figure 13 : Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Calcium Channel Blockers, 2017-2031

Figure 14: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Renin Inhibitors, 2017-2031

Figure 15: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Alpha-blockers, 2017-2031

Figure 16: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Others, 2017-2031

Figure 17: Global Antihypertensive Drugs Market Value Share Analysis, by Type, 2017-2031

Figure 18: Global Antihypertensive Drugs Market Attractiveness Analysis, by Type, 2017-2031

Figure 19: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Primary Hypertension, 2017-2031

Figure 20: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Secondary Hypertension, 2017-2031

Figure 21: Global Antihypertensive Drugs Market Value Share Analysis, by Medication Type, 2017-2031

Figure 22: Global Antihypertensive Drugs Market Attractiveness Analysis, by Medication Type, 2017-2031

Figure 23: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Monotherapy, 2017-2031

Figure 24: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Combination Therapy, 2017-2031

Figure 25: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Fixed Dose Combinations, 2017-2031

Figure 26: Global Antihypertensive Drugs Market Value Share Analysis, by Distribution Channel, 2017-2031

Figure 27: Global Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 28: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2031

Figure 29: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2031

Figure 30: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Online Pharmacies, 2017-2031

Figure 31: Global Antihypertensive Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), by Others, 2017-2031

Figure 32: Global Antihypertensive Drugs Value Share, by Region, 2017-2031

Figure 33: Global Antihypertensive Drugs Attractiveness, by Region, 2017-2031

Figure 34: North America Antihypertensive Drugs Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031

Figure 35: North America Antihypertensive Drugs Market Value Share Analysis, by Country, 2017-2031

Figure 36: North America Antihypertensive Drugs Market Attractiveness Analysis, by Country, 2017-2031

Figure 38: North America Antihypertensive Drugs Market Value Share Analysis, by Therapy Type, 2017-2031

Figure 39: North America Antihypertensive Drugs Market Attractiveness Analysis, by Therapy Type, 2017-2031

Figure 40: North America Antihypertensive Drugs Market Value Share Analysis, by Type, 2017-2031

Figure 41: North America Antihypertensive Drugs Market Attractiveness Analysis, by Type, 2017-2031

Figure 42: North America Antihypertensive Drugs Market Value Share Analysis, by Medication Type, 2017-2031

Figure 43: North America Antihypertensive Drugs Market Attractiveness Analysis, by Medication Type, 2017-2031

Figure 44: North America Antihypertensive Drugs Market Value Share Analysis, by Distribution Channel, 2017-2031

Figure 45: North America Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 46: Europe Antihypertensive Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

Figure 47: Europe Antihypertensive Drugs Market Value Share Analysis, by Country/Sub-region, 2017-2031

Figure 48: Europe Antihypertensive Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

Figure 49: Europe Antihypertensive Drugs Market Value Share Analysis, by Therapy Type, 2017-2031

Figure 50: Europe Antihypertensive Drugs Market Attractiveness Analysis, by Therapy Type, 2017-2031

Figure 51: Europe Antihypertensive Drugs Market Value Share Analysis, by Type, 2017-2031

Figure 52: Europe Antihypertensive Drugs Market Attractiveness Analysis, by Type, 2017-2031

Figure 53: Europe Antihypertensive Drugs Market Value Share Analysis, by Medication Type, 2017-2031

Figure 54: Europe Antihypertensive Drugs Market Attractiveness Analysis, by Medication Type, 2017-2031

Figure 55: Europe Antihypertensive Drugs Market Value Share Analysis, by Distribution Channel, 2017-2031

Figure 56: Europe Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 57: Asia Pacific Antihypertensive Drugs Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

Figure 58: Asia Pacific Antihypertensive Drugs Market Value Share Analysis, by Country/Sub-region, 2017-2031

Figure 59: Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

Figure 60: Asia Pacific Antihypertensive Drugs Market Value Share Analysis, by Therapy Type, 2017-2031

Figure 61: Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis, by Therapy Type, 2017-2031

Figure 63: Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis, by Type, 2017-2031

Figure 64: Asia Pacific Antihypertensive Drugs Market Value Share Analysis, by Medication Type, 2017-2031

Figure 65: Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis, by Medication Type, 2017-2031

Figure 66: Asia Pacific Antihypertensive Drugs Market Value Share Analysis, by Distribution Channel, 2017-2031

Figure 67: Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 68: Latin America Antihypertensive Drugs Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031

Figure 69: Latin America Antihypertensive Drugs Market Value Share Analysis, by Country/Sub-region, 2017-2031

Figure 70: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

Figure 71: Latin America Antihypertensive Drugs Market Value Share Analysis, by Therapy Type, 2017-2031

Figure 72: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Therapy Type, 2017-2031

Figure 73: Latin America Antihypertensive Drugs Market Value Share Analysis, by Type, 2017-2031

Figure 74: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Type, 2017-2031

Figure 75: Latin America Antihypertensive Drugs Market Value Share Analysis, by Medication Type, 2017-2031

Figure 76: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Medication Type, 2017-2031

Figure 77: Latin America Antihypertensive Drugs Market Value Share Analysis, by Distribution Channel, 2017-2031

Figure 78: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 79: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031

Figure 80:  Middle East & Africa Antihypertensive Drugs Market Value Share Analysis, by Country/Sub-region, 2017-2031

Figure 81: Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

Figure 82: Middle East & Africa Antihypertensive Drugs Market Value Share Analysis, by Therapy Type, 2017-2031

Figure 83: Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis, by Therapy Type, 2017-2031

Figure 84: Middle East & Africa Antihypertensive Drugs Market Value Share Analysis, by Type, 2017-2031

Figure 85: Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis, by Type, 2017-2031

Figure 86: Middle East & Africa Antihypertensive Drugs Market Value Share Analysis, by Medication Type, 2017-2031

Figure 87: Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis, by Medication Type, 2017-2031

Figure 88: Middle East & Africa Antihypertensive Drugs Market Value Share Analysis, by Distribution Channel, 2017-2031

Figure 89: Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 78: Latin America Antihypertensive Drugs Market Attractiveness Analysis, by Distribution Channel, 2017-2031

Figure 79: Middle East & Africa Antihypertensive Drugs Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017-2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

290

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved